Real-World Dexcom CGM Use in T2D NIT—Reduced Diabetes Distress and Improved Self-Care Behaviors

Introduction and Objective: CGM is emerging as a powerful tool for behavior modification in diabetes and is increasingly being used by individuals with Type 2 Diabetes (T2D). This real-world, observational study aimed to evaluate changes in glucose metrics, self-care behaviors, and diabetes-related psychosocial outcomes over 3 months of Dexcom G7 CGM use in a T2D population not using insulin (NIT). Methods: T2D NIT participants from the Dexcom Global Registry study wore Dexcom G7 CGM for 3 months. Patient reported outcome (PRO) surveys were administered at baseline and after 3 months to assess health behaviors and diabetes-related psychosocial status. Data were analyzed for the full population and stratified by age, gender, and race. Results: Sample included 156 T2D NIT participants (mean±SD age 63±11 years; BMI 30±6 kg/m2; 37% female; 10% Asian, 15% Black, 9% Other, 66% White). Over the 3 months, the overall population demonstrated significant reductions in diabetes-related distress; decreased consumption of sugary drinks, desserts, and alcohol, and increased adherence to healthy eating plans and exercise routines (all p<0.05). Participants age <45 years experienced clinically significant improvement in TIR (68 ± 35 to 86 ± 17) and reduction in time >250 mg/dL (13 ± 23 to 2±3) from first to last 10 days (p<0.05). Women reported higher baseline diabetes-related distress than men, which significantly decreased over the CGM wear period (p<0.05). Additional subgroup analyses revealed nuanced differences in glycemic, psychosocial, and behavioral aspects of diabetes, varying by age (<45 vs 45-64 vs 65+ years), gender (female vs male), and race (non-White vs White). Conclusion: Dexcom G7 use in the T2 NIT population is associated with reduced diabetes-related distress and improved self-management, particularly in dietary and physical activity domains. The magnitude and nature of behavioral and glycemic changes varied by demographic factors, underscoring the need for tailored interventions. Disclosure: M.A. Crawford: Employee; Dexcom, Inc. C. Hicks: Employee; Dexcom, Inc. K.E. Elkind-Hirsch: Other Relationship; Dexcom, Inc. Research Support; Dexcom, Inc. Advisory Panel; Lilly USA LLC. Research Support; Novo Nordisk A/S. Advisory Panel; Novo Nordisk A/S. H. Singh: Employee; Dexcom, Inc.